NCLT approves Bajaj Healthcare acquisition of Genrx Pharmaceuticals

Listed-company acquisitionScheme filed with the NCLTStrategic Transactions View source PDF Explain this filing

BAJAJHCARE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.6%Reaction day

₹331.10

prior close

₹333.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.6%+4.3% vs market

Pharmaceuticals peers, median of 172sector-0.6%+3.3% vs sector

On the reaction day the stock moved 4.3 pts more than Nifty Microcap 250 and 3.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.8

10m

-1.4

15m

-1.7

30m

-1.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.6-1.6+4.3-0.6+3.3

Next day

+4.8-1.0+5.8-0.7+5.5

+2.7-2.6+5.3-1.9+4.6

-2.1-5.1+3.0-3.5+1.4

-2.1-6.1+4.0-4.4+2.2

-6.1-8.3+2.2-6.0-0.1

-6.1-6.4+0.3-2.8-3.2

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Bajaj Healthcare has received an NCLT Mumbai order dated October 13, 2026 approving its acquisition of Genrx Pharmaceuticals (in Liquidation) on a going concern basis. Genrx will become a Wholly Owned Subsidiary of Bajaj Healthcare once the terms of the NCLT order are implemented. The acquisition application was filed earlier in 2025. The trading window for dealing in Bajaj Healthcare securities remains closed for designated persons.

Likely market impact

Genrx to become wholly owned subsidiary of Bajaj Healthcare per NCLT approval. Deal terms not yet disclosed, may expand pharma portfolio.